课题基金 / 基金详情

A New Era of Targeted Drug Discovery and the Path of Development: From Molecular

A New Era of Targeted Drug Discovery and the Path of Development: From Molecular
靶向药物发现的新时代及发展路径:从分子开始
批准号:
8335603
负责人:
Gabrielle Gold-von Simson
金额:
$9.44万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-07-01 至 2017-06-30
关键词:
AchievementAddressAdvisory CommitteesAmericasAreaBackBasic ScienceBehavioral ResearchBeliefBiomedical ResearchBreathingBusinessesCapitalCardiovascular DiseasesCase StudyClinical ResearchClinical TrialsCollaborationsComplications of Diabetes MellitusCost AnalysisDataDevelopmentDiabetes MellitusDiabetic NephropathyDisciplineDiseaseDoctor of PhilosophyDrug Delivery SystemsDrug MonitoringEconomicsEducational ActivitiesEducational CurriculumEducational StatusEducational process of instructingEnsureEthicsEvaluationFacultyFailureFutureGoalsGrantHealthHealth PolicyIndividualIndustryInvestmentsKnowledgeLegal patentLogisticsManuscriptsMarketingMetricMissionMolecularNational Institute of Diabetes and Digestive and Kidney DiseasesNatural regenerationNatureObesityOutcomeOutcome MeasureParticipantPathway interactionsPatient CarePatient Self-ReportPatientsPerformancePharmaceutical PreparationsPharmacologic SubstancePhasePress ReleasesProcessProgram DevelopmentPublic HealthPublic OpinionQualitative EvaluationsQuantitative EvaluationsRecommendationRegulationReportingResearchResearch InfrastructureResearch PersonnelResourcesRetinal DiseasesRewardsRunningSafetySchoolsScientistSeriesShapesSignal PathwaySignal TransductionSpecific qualifier valueStimulusStudentsSurveysTask PerformancesTechnologyTherapeuticTherapeutic InterventionTrainingTranslatingTranslational ResearchUnited States National Institutes of HealthWorkWritingbasebench to bedsidedesigndrug developmentdrug discoveryexperiencefallsfollow-uphealth practiceimprovedinnovationinterestmeetingsmultidisciplinarynewsnovelpost-marketprogramsresearch and developmentskillssuccesssymposiumtool

项目摘要

项目成果

Gabrielle Gold-von Simson的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): We propose to modify a series of courses into a highly relevant NIDDK educational activity. {Despite promising clinical studies in patients with diabetic complications, such as diabetic nephropathy, retinopathy and cardiovascular disease as examples, pharmaceutical companies have been reluctant to pursue drug development in this important area. NIDDK has duly stepped in with several initiatives to support research and drug development for diabetic complications. As such, our ultimate goal will be to teach a diverse group of targeted learners at the graduate level and beyond} to harness novel bench-to-bedside empirical knowledge in their research {and related endeavors} with a focus on diabetes, {diabetic complications}, and obesity, specific, comorbid, and pervasive public health problems. {We will highlight the importance of designing therapeutic interventions based on target changes during the disease; for example, some targets may be more relevant in initiation, others more in progression, and some more in failure of regression and regeneration.} The programmatic theme that emphasizes translation of research discoveries to patient care will be drug discovery and development. The current yearlong course series reviews Phase I-IV trials, post- marketing trajectories, safety monitoring, drug patents, and economic stimulus reform as well as ethics and cost analysis in the fall semester. In the spring semester, the molecular pathways and scientific basis of successful and unsuccessful drugs are discussed. Our preliminary experience has established that together, the two course segments (and ongoing didactic seminar series) help to disabuse the limiting belief that individuals cannot directly work towards inventing drugs, and the educational activity directs the diverse interests of this wide range of trainees towards the inspirations and rewards of translating basic science discoveries into useful patient care tools. Qualitative and quantitative reporting tools and performance tasks will evaluate the program to assure achievement of educational goals as well as future expansion of the program. Progress in achieving these objectives would mean increased NIDDK-relevant translational research skills for the diverse participants to ultimately improve patient care and public health. PUBLIC HEALTH RELEVANCE: Drug discovery and development is a broad, multidisciplinary process that integrates all components of the translational question and continuum, from molecular signaling pathways at the bench to public health policies and practice standards. Our goal is to implement a unique educational activity that will encompass the many essential features of this innovative process. Achievement of this program's goals may make an identifiable contribution towards ensuring that highly trained scientists will be available in adequate numbers and in appropriate scientific areas to address the nation's biomedical, behavioral, and clinical research needs in the NIDDK's mission areas {specifically diabetes, diabetic complications, and obesity as areas of focus in this proposed educational program}.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Biomedical Entrepreneurship Skills Development Program for the Advancement of Research Translation
Biomedical Entrepreneurship Skills Development Program for the Advancement of Research Translation
Biomedical Entrepreneurship Skills Development Program for the Advancement of Research Translation
A New Era of Targeted Drug Discovery and the Path of Development: From Molecular
海外基金